Understand the source comparison
Growth Hormone Secretagogues vs Tissue-Repair Peptides
Two distinct peptide categories serve different functions in combat sports protocols. Growth hormone secretagogues (GHRP-2, GHRP-6, Ipamorelin, MK-677) stimulate the pituitary gland to release endogenous GH in pulsatile waves. Mimicking natural circadian GH se
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Two distinct peptide categories serve different functions in combat sports protocols. Growth hormone secretagogues (GHRP-2, GHRP-6, Ipamorelin, MK-677) stimulate the pituitary gland to release endogenous GH in pulsatile waves. Mimicking natural circadian GH secretion patterns. Tissue-repair peptides (BPC-157, TB-500) act locally at injury sites through receptor binding and growth factor upregulation. Confusing the two leads to protocol failures. Using a secretagogue to address a rotator cuff injury misses the target entirely.
- GHRP-2 binds to ghrelin receptors in the hypothalamus and pituitary, triggering GH release without suppressing the body's own production. Unlike exogenous GH administration, secretagogues preserve the natural feedback loop. The pituitary still responds to endogenous signals. Typical research doses range from 100–300 mcg subcutaneously, administered 2–3 times daily on an empty stomach to avoid glucose-induced GH suppression. MK-677, an orally active ghrelin mimetic, produces sustained GH elevation over 24 hours with a single daily dose. Making it logistically simpler for athletes with unpredictable training schedules. The MK 677 product available through research suppliers maintains potency for 28 days post-reconstitution when stored at 2–8°C.
- BPC-157, a synthetic pentadecapeptide derived from gastric protective protein BPC, accelerates healing across multiple tissue types. Research published in the Journal of Physiology and Pharmacology demonstrates enhanced angiogenesis, collagen deposition, and inflammatory resolution in tendon, ligament, and muscle injuries. Standard research protocols use 250–500 mcg doses administered subcutaneously near the injury site or intramuscularly for systemic effects. TB-500, the active fragment of thymosin beta-4, promotes cell migration and differentiation. Particularly effective for muscle tears and chronic tendinopathy. Loading doses of 5–10 mg twice weekly for 4–6 weeks, followed by maintenance doses of 2–5 mg monthly, represent typical research frameworks. Our team has observed that combining tissue-repair peptides with secretagogues produces synergistic effects. The elevated IGF-1 from GH stimulation enhances the angiogenic response to BPC-157, accelerating overall recovery timelines.